Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Comparative Immunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1471412

Comparative pharmacokinetics of porcine and human anti-influenza hemagglutinin monoclonal antibodies in outbred and minipigs

Provisionally accepted
Basudev Paudyal Basudev Paudyal 1*Elliot Moorhouse Elliot Moorhouse 1Bhawna Sharma Bhawna Sharma 1Michael Dodds Michael Dodds 2Victor Nguyen Victor Nguyen 3Mark Milad Mark Milad 3Elma Tchilian Elma Tchilian 1*
  • 1 The Pirbright Institute, Woking, United Kingdom
  • 2 Certara (United States), Princeton, New Jersey, United States
  • 3 Milad Pharmaceutical Consulting LLC, Plymouth, Michigan, United States

The final, formatted version of the article will be published soon.

    Assessing pharmacokinetics of monoclonal antibodies (mAbs) in relevant animal models is essential for designing improved formulations and developing mAb delivery platforms. We have established the pig, a large natural host animal for influenza with many similarities to humans, as a robust model for testing the therapeutic efficacy of anti-influenza mAbs and evaluating mAb delivery platforms. Here we compared the pharmacokinetic characteristics of two anti-influenza hemagglutinin mAbs, human 2-12C and porcine pb27 in Göttingen minipigs and Landrace × Large White outbred pigs. Minipigs offer the advantage of more stable weight, while outbred pigs are more readily available but exhibit rapid growth. Both outbred and minipigs showed similar pharmacokinetics and half-life of porcine pb27 (half-life of 15.7 days for outbred and 16.6 days for minipigs). In contrast, the half-life of human 2-12C was more rapid in two of the minipigs, but not in the outbred pigs, correlating with the development of antidrug antibodies (ADA) in the two minipigs. Our results demonstrate that both outbred and minipigs are appropriate models for pharmacokinetic studies and evaluation of mAb delivery platforms, potentially bridging the gap between small animals and human trials.

    Keywords: pharmacokinetic, anti-influenza monoclonal antibodies, Minipigs, Outbred pigs, 2-12C, pb27

    Received: 27 Jul 2024; Accepted: 30 Sep 2024.

    Copyright: © 2024 Paudyal, Moorhouse, Sharma, Dodds, Nguyen, Milad and Tchilian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Basudev Paudyal, The Pirbright Institute, Woking, United Kingdom
    Elma Tchilian, The Pirbright Institute, Woking, United Kingdom

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.